All In Biotech

Drug Trial Radar · NCT07841977

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

A Phase 2 Proof-of-Concept Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Active Treatment Extension Period to Assess the Safety and Efficacy of Seladelpar and Cilofexor in Combination for Primary Biliary Cholangitis

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 2028

Study completion Jun 2034

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC). The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.

Conditions

  • Primary Biliary Cholangitis

Interventions

  • SeladelparDrug

    Capsule administered orally

  • PTM SeladelparDrug

    Capsule administered orally

  • Cilofexor Dose BDrug

    Tablet administered orally

  • PTM Cilofexor Dose ADrug

    Tablet administered orally

  • PTM Cilofexor Dose BDrug

    Tablet administered orally

  • Cilofexor Dose ADrug

    Tablet administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Serum Concentration of Alkaline Phosphate (ALP) at Week 24Time frame: Baseline, Week 24
  2. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose up to 30 days post last dose (up to 318 weeks)
  3. Percentage of Participants Experiencing Serious Adverse Events (SAEs)Time frame: First dose up to 30 days post last dose (up to 318 weeks)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • Florida Research Institute

    Lakewood Rch, Florida · Recruiting

  • Digestive Healthcare of Georgia

    Atlanta, Georgia · Recruiting

  • GI Associates of Northeast Tennessee

    Johnson City, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.